Mikhail Blagosklonny

Great Work of Mikhail Blagosklonny in the Field of Research.

The immunity for the old humans marked the celebration year at 2014. It was seen to be the turning point in the field of research and the quest on the matters of immortality. This was a new foundation that had been predicted some years back by the experts, and it came to the past. The research was primarily based on the cause of the human death if the idea of aging was put aside. The call for the research was shoved by the unscientific misguided information that had no ground of substantiation.In the recent past, aging of the human being was thought to be the functional decline of the organs due to the pile up of the damaged molecules in the body. The disapproving information that was based on the broad scientific research indicated that the aging is part of the growth that marks the signal pathway of the TOR (Target of Rapamycin). The centric model of the TOR shows that the aging of the human beings can be treated with rapamycin. Additionally, its shows that the features of the rapamycin and other substance that plays the similar roles such as rapalogs extends the life of the human being.

The explanation of the theory faced a lot of repulsion by the many opponents though it had been predicted earlier. Most of them were taking the idea of the TOR-centric as just mere say without any proof.The study that is based on the rapamycin analog as revealed by the experts attracted the attention of many on its founding that it can boost the immunity and reduce the aging. The results were seen to force many to switch to using “fountain of youth” drug to delay the effects of aging. Nir Barzilai through is brief explanation addressed that the encouragement use of it was to target the improvement of the aging and it was a part of achievement in their field of research.Mikhail Blagosklonny is a professional professor in the sphere of Oncology. He is among the research team at the Roswell Park Cancer Institute. He specialized in matters related to the aging and cancer. He earned MD in Internal Medicine from the First Pavlov State Medical University. He then furthered his studies in Ph.D. at Experimental Medicine and Cardiology.

Through his pragmatic skills in the field of research, he held the post of the associate professor of medicine that gives the guideline on the research matters at New York Medical College. He then made his way to serve as a senior scientist at Ordway Research Institute. Finally, in the year 2009, he joined other researchers at Roswell Park Cancer Institute. His expertise in the field of research was contributed by the skills that he gained while working at different places. The primary area of concern he is interested in is Biogerontology. Mikhail Blagosklonny plays a role of the chief editor of Oncotarget and Cell Cycle. He also assists as an editor in other areas such as therapy and cancer biology. Additionally, he was elected to be one of the board members of the Cell Death and Differentiation board.Mikhail Blagosklonny has made a lot of contribution in the area of research as a scientist.

Gary